Hematopoietic stem cell remobilization with vinorelbine and filgrastim in AML

V. Blum(University of Bern), Thomas Pabst(University Hospital of Bern), Urban Novak(University of Bern), Mario Bargetzi(Kantonsspital Aarau), Katja Seipel(University of Bern), Kurt Leibundgut(Swiss Red Cross), Gabriela M. Baerlocher(Terry Fox Research Institute), Behrouz Mansouri Taleghani(University of Bern), Yara Banz(Beth Israel Deaconess Medical Center), Alexander D. Heini(University of Bern)

Bone Marrow Transplantation

February 13, 2017

10.1038/bmt.2017.2

Cited by 7

Related Papers

Mutations in <i>TERT,</i> the Gene for Telomerase Reverse Transcriptase, in Aplastic Anemia

|New England Journal of Medicine|2005|717

Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML)

|Leukemia|2012|417

Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants

|Leukemia|2017|339

Deep Molecular Response Is Reached by the Majority of Patients Treated With Imatinib, Predicts Survival, and Is Achieved More Quickly by Optimized High-Dose Imatinib: Results From the Randomized CML-Study IV

|Journal of Clinical Oncology|2013|299

Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV

|Blood|2011|289